Abstract 159P
Background
To overcome the common Temozolomide (TMZ) resistance in Glioblastoma (GBM), targeting certain receptors such as GPCRs can be of benefit as they are involved in cancer treatment response signalling pathways. One attractive target is KISS1R, activated by Kisspeptin. RNA-Seq of male GBM samples revealed elevated KISS1R expression and low KISS1 expression, suggesting GBM as a paracrine tumour. By re-modulating KISS1R using exogenous kisspeptin (KP-10), we aimed to positively influence the cytotoxic effect of TMZ and investigate the underlying mechanism(s) in KISS1R-expressing GBM cells.
Methods
KISS1R expression was confirmed using RT-PCR. KP-10/TMZ IC50 was determined using MTT cell viability assay and synergistic combinations were analysed using Isobologram analysis with non-constant ratio. Pathway prediction was done using KEGG, Wikipathways and STITCH. Flow cytometry and live-cell imaging identified molecular mechanisms while relevant markers were assessed via JESS simple Westren. LC-MS/MS was used to identify relevant DEPs with Kaplan-Meier survival analysis to identify clinical relevance.
Results
KISS1R expression was confirmed in A-172 (p53 wild-type) and LN-18 (p53 mutant). KP-10/TMZ treatment demonstrated high synergism in both cells. Pathway analysis of KP-10/TMZ predicted interaction at apoptosis, cytoprotective autophagy and DNA damage. This was further confirmed with elevated autophagy marker p62 in A-172, while increased expression of DNA damage and repair markers PARP and γH2AX in LN-18. The proteomic profiles showed DEPs related to RNA splicing, cytoplasmic translation and ER stress in A-172, while negative regulation of mRNA, glycolysis and MHC class 1 protein binding in LN-18. Ten common DEPs impacted GBM patients’ survival.
Conclusions
The response to KP-10/TMZ treatment varied based on the status of p53 of the GBM cell used and commonly impacted DEPs associated with the cytoplasmic translation of proteins and regulation of mRNA, more seen in LN-18 (p53 mutant). This underscores the significance of delving into the concept of dormant cells within a single tumour to correlate the results from the in-vitro GBM model to actual GBM patients.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
JCSMHS, Monash University Seed Grand and Monash Merit scholarship and funding for doctoral research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163TiP - Single-institution, single-arm, open-label phase II basket study of mutation and/or elevated hedgehog (Hh) expression-directed smoothened inhibitor sonidegib in patients with advanced solid malignancies
Presenter: Madhawa De Silva
Session: Cocktail & Poster Display session
Resources:
Abstract
164TiP - MONSTAR-GLYCO: A multi-institutional prospective study harnessing glycomics and multi-omics on the j-glyconet and SCRUM-MONSTR platform
Presenter: Tadayoshi Hashimoto
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Unravelling HR-positive, HER2-negative breast cancer and its tumor microenvironment heterogeneity using spatial transcriptomics
Presenter: Bengisu Karakose
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Tumor microenvironment (TME) and PD-L1 expression heterogeneity in high grade serous ovarian cancer (HGSC) samples analysis from the randomized NeoPembrOV/GINECO phase II trial
Presenter: Laetitia Collet
Session: Cocktail & Poster Display session
Resources:
Abstract
169P - Tumour microenvironment in glioblastoma: A single-cell perspective on macrophage dynamics and T cell exhaustion
Presenter: Farasat Kazmi
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - Digital spatial profiling to uncover biomarkers for response prediction in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy
Presenter: Chiara Molinari
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Immune-modulatory drug profiling using perfused, microfluidic on-chip co-cultures of patient-derived ovarian cancer microtumors and autologous immune cells
Presenter: Sarah Plöger
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - The impact of androgen ablation on the immune landscape in therapy-resistant prostate cancer: Insights from tumour microenvironment analysis
Presenter: Jodi Stewart
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - NRF2 levels in high grade serous ovarian cancer: Characterization and treatment
Presenter: Helen Toma
Session: Cocktail & Poster Display session
Resources:
Abstract